Eric Easom - 20 Feb 2026 Form 4 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: ANTX
Reported as of: 20 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Feb 2026, 16:36:44 UTC
Prior SEC filing: 03 Jun 2025
Next SEC filing: 23 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Lucy Day, Attorney-in-Fact for Eric Easom

Key filing fact

Eric Easom filed Form 4 for AN2 Therapeutics, Inc. (ANTX) on 23 Feb 2026.

Key facts

This page summarizes Eric Easom's Form 4 filing for AN2 Therapeutics, Inc. (ANTX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 23 Feb 2026, 16:36.

Change

Previous filing in this sequence was filed on 03 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001914503 Primary reporting owner

Easom Eric

Relationship: Chief Executive Officer, Director
Address: C/O AN2 THERAPEUTICS, INC., 1300 EL CAMINO REAL, SUITE 100, MENLO PARK
Signature: /s/ Lucy Day, Attorney-in-Fact for Eric Easom
Signature date: 23 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ANTX transaction

Common Stock

Award

Transaction value: $0
Shares: +112,250
Change %: +44%
Price: $0.000000
Shares after: 368,630
Date: 20 Feb 2026
Ownership: Direct
Footnotes: F1, F2

ANTX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,065,766
Date: 20 Feb 2026
Ownership: See Footnote
Footnotes: F3

ANTX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 97,058
Date: 20 Feb 2026
Ownership: See Footnote
Footnotes: F4

ANTX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 97,058
Date: 20 Feb 2026
Ownership: See Footnote
Footnotes: F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ANTX transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +224,500
Change %
Price: $0.000000
Shares after: 224,500
Date: 20 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 224,500
Exercise price: $1.04
Footnotes: F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Represents restricted stock units ("RSUs") which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2026, subject to the Reporting Person's continuous service through each applicable vesting date.

Footnote F2

Includes a balance of (i) 145,250 RSUs which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2025 and (ii) 99,000 RSUs which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2024, in each case subject to the Reporting Person's continuous service through each applicable vesting date.

Footnote F3

Consists of shares of Common Stock held by the Easom Living Trust dated August 21, 2019.

Footnote F4

Consists of shares of Common Stock held by the C. Easom Irrevocable Trust dated October 8, 2021.

Footnote F5

Consists of shares of Common Stock held by the Jude Easom Irrevocable Trust dated October 8, 2021.

Footnote F6

The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2026, subject to the Reporting Person's continuous service through each applicable vesting date.